@inbook{ce156ba7c9144060a564d029998502c0,
title = "Understanding the genetic basis for cholangiocarcinoma",
abstract = "Cholangiocarcinoma is associated with several different risk factors, many of which have known genetic associations. Advances in our understanding of the human genome have translated to the development of gene specific and whole genome assays for identifying gene variants and other alterations associated with cancer development. An improved understanding of the inherited genetic variants associated with risk of cholangiocarcinoma has the potential to improve our understanding of the basic biology of cholangiocarcinoma, enhance the performance of risk stratification models for identifying individuals at highest risk for cholangiocarcinoma, and identifying genetic variants associated with predisposition to cholangiocarcinoma in families with multiple affected individuals. It is increasingly recognized that major cancer-causing mutations or other gene alterations associated with familial risk of multiple cancers can also occur as germline events in individuals with apparently sporadically occurring cancer. In this chapter we review the major risk factors for cholangiocarcinoma as well as known gene variants associated with these risk factors, gene variants that have been associated with cholangiocarcinoma as the result of interrogation of candidate genes known to be associated with putative cancer causing pathways in cholangiocarcinoma, as well as the prevalence of major cancer causing genetic aberrations shown to be inherited in the germline of patients with sporadically developed cholangiocarcinoma. There has not yet been any large-scale genome wide association study of cholangiocarcinoma, and the results from such a study are eagerly anticipated.",
keywords = "Cholangiocarcinoma (CCA), Genome wide association studies, Germline mutations, Pathogenic germline alterations studies, Single nucleotide polymorphisms",
author = "Schmidt, {Mikayla A.} and Roberts, {Lewis R.}",
note = "Funding Information: M.A.S. has no financial or personal disclosures relevant to the contents of this manuscript. L.R.R. reports grants from NIH (CA186566 and CA210964), Mayo Clinic, The Cholangiocarcinoma Foundation, Bayer, Boston Scientific, Exact Sciences, Fujifilm Medical Sciences, Gilead Sciences, Glycotest Inc., PSC Partners Seeking a Cure, Redhill Biopharma, and TARGET PharmaSolutions during the conduct of the study; other support from MedEd Design LLC, Pontifax, Global Life Science Consulting, The Lynx Group, AstraZeneca, Bayer, Eisai, Exact Sciences, and GRAIL Inc. Publisher Copyright: {\textcopyright} 2022 Elsevier Inc.",
year = "2022",
month = jan,
doi = "10.1016/bs.acr.2022.03.004",
language = "English (US)",
isbn = "9780323983921",
series = "Advances in Cancer Research",
publisher = "Academic Press Inc",
pages = "137--165",
editor = "Sirica, {Alphonse E.} and Sirica, {Alphonse E.} and Fisher, {Paul B.}",
booktitle = "Hepatobiliary Cancers",
}